2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Infections
9
Lymphoma
7
Leukemia
6
Neoplasms, Plasma Cell
5
Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Urinary Tract Infections
2
Prostatic Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocythemia, Essential
1
Surgical Wound Infection
1
Skin Neoplasms
1
Sezary Syndrome
1
Sepsis
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Interventions
plerixafor
2
Lenalidomide
2
ofatumumab
1
gamma-Globulins
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Saline Solution
1
SARS-CoV-2 inactivated vaccines
1
Panzyga
1
Influenza Vaccines
1
Immunoglobulins
1
Hizentra
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Agammaglobulinemia
×
Trimethoprim, Sulfamethoxazole Drug Combination
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled